Current therapies for systemic lupus erythematosus (SLE) include corticosteroids as a
persistent mainstay and traditional immunosuppressants which are given according to …

Objectives To evaluate the long-term safety and efficacy of belimumab in patients with
systemic lupus erythematosus (SLE) from Japan and South Korea. Methods In this phase III …

Introduction: Systemic lupus erythematosus (SLE) is a systemic autoimmune inflammatory
disease with extensive clinical variability. In 2011, the anti-BAFF monoclonal antibody …

Objectives Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus
(SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic …

Objective To assess the efficacy and safety of subcutaneous (SC) belimumab in patients
with systemic lupus erythematosus (SLE). Methods Patients with moderate‐to‐severe SLE …

Objective. To evaluate the efficacy/safety of belimumab plus standard therapy in patients (n=
449) with active systemic lupus erythematosus (SLE) treated up to 7 years (n= 177 currently …

Objective To assess the safety, tolerability, biologic activity, and efficacy of belimumab in
combination with standard of care therapy (SOC) in patients with active systemic lupus …

Systemic lupus erythematosus (SLE) continues to have important morbidity and accelerated
mortality despite therapeutic advances. Targeted therapies offer the possibility of improved …

In recent years, advances in the treatment and management of patients with systemic lupus
erythematosus (SLE) have improved their life expectancy and quality of life. However, lupus …

AIMS OF THE STUDY To describe patterns of systemic lupus erythematosus (SLE) care and
the clinical effectiveness of belimumab plus standard of care therapy in a real-world clinical …